IN2014DN09445A - - Google Patents

Info

Publication number
IN2014DN09445A
IN2014DN09445A IN9445DEN2014A IN2014DN09445A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A IN 9445DEN2014 A IN9445DEN2014 A IN 9445DEN2014A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A
Authority
IN
India
Prior art keywords
protein complexes
viral proteins
engineered viral
vaccine
methods
Prior art date
Application number
Inventor
Christopher Patrick Marshall
Original Assignee
Marshall Christophe R Patrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marshall Christophe R Patrick filed Critical Marshall Christophe R Patrick
Publication of IN2014DN09445A publication Critical patent/IN2014DN09445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross -links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
IN9445DEN2014 2012-05-09 2013-05-09 IN2014DN09445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Publications (1)

Publication Number Publication Date
IN2014DN09445A true IN2014DN09445A (en) 2015-07-17

Family

ID=49548782

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9445DEN2014 IN2014DN09445A (en) 2012-05-09 2013-05-09

Country Status (7)

Country Link
US (6) US20130302366A1 (en)
EP (2) EP3483174A1 (en)
JP (4) JP2015518819A (en)
AU (5) AU2013259548A1 (en)
CA (1) CA2873048C (en)
IN (1) IN2014DN09445A (en)
WO (1) WO2013169961A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6685903B2 (en) * 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー RSV pre-fusion F protein that is conformationally stabilized
WO2015020913A2 (en) 2013-08-03 2015-02-12 Marshall Christopher Patrick Influenza hemagglutinin proteins and methods of thereof
EP3664836A4 (en) 2017-08-07 2021-05-19 Calder Biosciences Inc. CONFORMITY STABILIZED RSV-F PREFUSION PROTEINS
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
MX2022014224A (en) * 2020-05-12 2023-02-23 Univ California Sars-cov2 neutralizing single domain antibody constructs.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6534064B1 (en) 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
ATE513056T1 (en) 1999-10-15 2011-07-15 Avatar Medical L L C STABILIZED PROTEINS
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
WO2003052122A2 (en) 2001-12-17 2003-06-26 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Gp41 inhibitor
US20080206264A1 (en) 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
EP1641813B1 (en) * 2003-07-03 2011-11-09 Avatar Biotechnologies, Inc. Methods for obtaining molecules with reduced immunogenicity
JP5069558B2 (en) * 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション Stable peptidomimetic of HIV gp41 fusion intermediate
CA2655934A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
KR101351195B1 (en) * 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 Novel immunogenic epitopes for immunotherapy
CN103298935A (en) 2007-08-15 2013-09-11 阿穆尼克斯公司 Compositions and methods for improving the performance of biologically active polypeptides
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
SMT202000101T1 (en) * 2008-10-10 2020-03-13 Childrens Medical Center Biochemically stabilized hiv-1 env trimer vaccine
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
US20130236905A1 (en) 2010-05-18 2013-09-12 Christopher Marshall Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
US20130149336A1 (en) * 2011-10-27 2013-06-13 Brian L. Hjelle Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof

Also Published As

Publication number Publication date
AU2019216695A1 (en) 2019-09-05
JP6692853B2 (en) 2020-05-13
JP2020125323A (en) 2020-08-20
CA2873048A1 (en) 2013-11-14
US20180117116A1 (en) 2018-05-03
US20130302366A1 (en) 2013-11-14
AU2021204169B2 (en) 2023-11-23
AU2021204169A1 (en) 2021-07-15
US10155023B2 (en) 2018-12-18
JP2018150330A (en) 2018-09-27
AU2018200502B2 (en) 2019-10-03
CA2873048C (en) 2020-10-27
AU2018200502A1 (en) 2018-02-15
US20190105368A1 (en) 2019-04-11
AU2013259548A1 (en) 2014-11-27
EP3483174A1 (en) 2019-05-15
US11752191B2 (en) 2023-09-12
JP2022163180A (en) 2022-10-25
US20240238369A1 (en) 2024-07-18
US20210322512A1 (en) 2021-10-21
EP2846828A1 (en) 2015-03-18
EP2846828B1 (en) 2018-11-21
JP7472209B2 (en) 2024-04-22
JP2015518819A (en) 2015-07-06
EP2846828A4 (en) 2015-07-01
US20130317205A1 (en) 2013-11-28
WO2013169961A1 (en) 2013-11-14
AU2024201200A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2024010676A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist.
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
MX364689B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
ZA202403393B (en) Synthetic chimeric poxviruses
WO2013054199A3 (en) Cmv antigens and uses thereof
EA202090699A3 (en) COMPOSITIONS CONTAINING A BUFFER, VACCINES THAT CONTAIN COMPOSITIONS CONTAINING A BUFFER, AND THEIR APPLICATION
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
WO2015052543A3 (en) Malaria vaccination
TN2018000180A1 (en) Polypeptides inhibiting cd40l
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
EA202090319A1 (en) PEPTIDE CONJUGATES, CONJUGATION METHOD AND THEIR USE
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
IN2014DN09445A (en)
MX363149B (en) Influenza nucleoprotein vaccines.
MX2017008406A (en) Amino acid and peptide conjugates and uses thereof.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019007924A (en) Influenza vaccines.
WO2015149016A3 (en) Breast and ovarian cancer vaccines
EP4548979A3 (en) Enhanced delivery of drugs to the brain
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers